The purpose of this study is to provide early access to Ibrutinib treatment for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and collect additional safety data while the medication is not commercially available.
This is an open-label (all people know the identity of the intervention), multi-center (when more than one hospital or medical school team work on a medical research study) early access program (EAP) study. The study will be conducted in 2 phases: a Screening Phase (approximately 30 days prior to administration of first dose) and a Program Drug Phase (Day 1 up to 30 Days after last dose of study drug). Enrolled participants will receive 420 milligram (mg) oral ibrutinib once daily on a 28-day cycle until disease progression, occurrence of unacceptable toxicity, no longer achieving clinical benefit, or the end of program. Treatment will be continuous (without interruption) and self-administered. Disease evaluations will be conducted according to local standard of care as clinically indicated. Participant's safety will be monitored throughout the study. All enrolled and on-going participants in the program will continue to receive ibrutinib by the EAP until marketing approval or 6 months after this date.
Drug: PCI-32765 (Ibrutinib)
Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
- Has Eastern Cooperative Oncology Group (ECOG) performance status of less than (=) 5,000/microliter (μl)
- Active disease meeting at least one of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria
- Must have received at least one prior therapy for CLL and not be appropriate for treatment or retreatment with purine analog based therapy
- Able to receive all outpatient treatment and all laboratorial monitoring at the institution that administers program drug
- Known central nervous system (CNS) lymphoma or leukemia
- Known prolymphocytic leukemia or history of or currently suspected Richter's transformation
- Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)
- Prior exposure to ibrutinib or randomization in an ibrutinib study
- Requires treatment with a strong Cytochrome P3A4/5 (that is, CYP3A4/5) Inhibitor
Janssen-Cilag Farmaceutica Ltda. Clinical Trial
Janssen-Cilag Farmaceutica Ltda.